Biblio
A 10-year retrospective analysis of Toxoplasma gondii qPCR screening in allogeneic hematopoietic stem cell transplantation recipients. Bone Marrow Transplant. 2022.
A 16-month-long experience of COVID-19 in allogeneic haematopoietic stem cell transplantation recipients: An SFGM-TC multicentre cohort study. Br J Haematol. 2023.
Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2022.
Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL-mutation. Eur J Haematol. 2019.
Allogeneic stem cell transplantation in therapy-related myelodysplasia after autologous transplantation for lymphoma: a retrospective study of the SFGM-TC. Biol Blood Marrow Transplant. 2019.
Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms. Br J Haematol. 2015.
Comparison of Allogeneic Stem Cell Transplantation and Non-Transplant Approaches in Elderly Patients with Advanced Myelodysplastic Syndrome: Optimal Statistical Approaches and a Critical Appraisal of Clinical Results Using Non-Randomized Data. PLoS One. 2013;8(10):e74368.
Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation. Haematologica. 2014.
. Family mismatched allogeneic stem cell transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of EBMT. Biol Blood Marrow Transplant. 2018.
Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity. Blood Adv. 2020;4(9):1824-1832.
GLCCI1 and GR genetic diversity and response to glucocorticoid-based treatment of graft-versus-host disease. Biol Blood Marrow Transplant. 2015.
Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines. Transplant Cell Ther. 2022.
High Number of memory T cells is associated with higher risk Of acute GVHD after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014.
. HLA mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis. Biol Blood Marrow Transplant. 2018.
Human-derived α1-antitrypsin is still efficacious in heavily pretreated patients with steroid-resistant gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2020.
Impact of acute and chronic Graft-vs-Host Disease on human B-cell generation and replication. Blood. 2014.
Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood. 2023.
Late Donor Bone Marrow Failure After Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation. 2014;97(12):e75-e77.
. Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS. Bone Marrow Transplant. 2023.
Outcome after transplantation according to reduced intensity conditioning regimen in patients transplanted for myelofibrosis. Biol Blood Marrow Transplant. 2016.
Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Pa. Bone Marrow Transplant. 2021.
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. J Clin Oncol. 2023:JCO2201784.